Covered recipient · General Payments record
NICOLE MARIE SANDERS
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2021–2024
$1,903.11
- Reported across 87 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $653.53 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $297.25 | 5 |
| Medtronic, Inc. | $129.42 | 1 |
| ABIOMED | $100.83 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $56.55 | 3 |
| CVRx Inc. | $30.55 | 3 |
| Lexicon Pharmaceuticals, Inc. | $22.03 | 1 |
| Amgen Inc. | $16.90 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABIOMED | $20.24 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142302281 | CMS |
| ABIOMED | $40.46 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142302283 | CMS |
| ABIOMED | $40.13 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142302285 | CMS |
| Amgen Inc. | $16.90 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117373652 | CMS |
| CVRx, Inc. | $21.41 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138614009 | CMS |
| CVRx, Inc. | $7.96 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138614011 | CMS |
| CVRx, Inc. | $1.18 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138614013 | CMS |
| Lexicon Pharmaceuticals, Inc. | $22.03 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1081712395 | CMS |
| Medtronic, Inc. | $129.42 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116941450 | CMS |
| Novartis Pharmaceuticals Corporation | $24.96 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087185619 | CMS |
| Novartis Pharmaceuticals Corporation | $17.34 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087185621 | CMS |
| Novartis Pharmaceuticals Corporation | $14.25 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087185641 | CMS |
| Novo Nordisk Inc | $126.97 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100423563 | CMS |
| Novo Nordisk Inc | $17.09 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100467786 | CMS |
| Novo Nordisk Inc | $26.73 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100245709 | CMS |
| Novo Nordisk Inc | $1.47 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100526113 | CMS |
| Novo Nordisk Inc | $124.99 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100558289 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.